Clinical Trials List
2021-05-01 - 2026-12-31
Phase II
Recruiting3
ICD-10C15.3
Malignant neoplasm of upper third of esophagus
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9150.0
Malignant neoplasm of cervical esophagus
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 陳盛裕 Division of Hematology & Oncology
- Tien-Hua Chen Division of Hematology & Oncology
- Chueh-Chuan Yen Division of Hematology & Oncology
- 李瑩琦 Division of Radiology
- 翁敬堯 Division of Radiology
- Jiun-I Lai Division of Hematology & Oncology
- 姜乃榕 Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
- 王彥博 Division of General Internal Medicine
- Sheng-Yu Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- JHE-CYUAN GUO Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- Kun-Huei Yeh Division of Hematology & Oncology
- 郭弘揚 Division of Hematology & Oncology
- TA-CHEN HUANG Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
180 participants
